SCHEMBL30297601

SCHEMBL30297601

COc1ccc2cc[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
POLB P06746 1/20 1.00
MAPK1 P28482 1/20 1.00
MAOA P21397 2/20 0.55
ESR1 P03372 1/20 0.55
AHR P35869 3/20 0.50
CMA1 P23946 1/20 0.50
TYR P14679 1/20 0.50
CYP2A6 P11509 2/20 0.48
CYP1A2 P05177 1/20 0.48
MAPT P10636 2/20 0.48
APP P05067 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SYK P43405 1/20 0.48
MMP12 P39900 1/20 0.47
ATM Q13315 1/20 0.47
MAOB P27338 1/20 0.46
GHSR Q92847 1/20 0.46
CCNE2 O96020 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417704 1.00 MEN1 (1.00) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL17597245 0.89 MEN1 (0.79) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL25277620 0.86 MEN1 (0.76) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL8187780 0.85 MEN1 (0.73) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL30620465 0.85 MEN1 (0.73) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL1224829 0.85 MEN1 (0.73) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL29475284 0.84 MEN1 (0.72) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL29992449 0.83 MEN1 (0.71) MEN1KMT2APOLBMAPK1MAOA
SCHEMBL74720 0.83 MEN1 (0.71) MEN1KMT2APOLBMAPK1MAOA
Ethoxycarbonyl Group SCHEMBL28929781 0.83 KMT2A (0.69) MEN1KMT2APOLBMAPK1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250327074-A1 THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) 2025-10-23 US disclosed
US-20250197376-A1 PYRAZINE AMIDE DERIVATIVES NOVARTIS AG (CH) 2025-06-19 US disclosed
US-20250108123-A1 COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2025-04-03 US disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
EP-4452936-A2 INDOLES, INDAZOLES, AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
EP-4447954-A1 HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS Icahn School of Medicine at Mount Sinai (US) 2024-10-23 EP disclosed
CN-117069725-A Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application 上海赛默罗生物科技有限公司 2023-11-17 CN disclosed
CN-111170999-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-06-30 CN disclosed
WO-2023122782-A2 INDOLES, INDAZOLES, AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed
CN-115057807-B 3- (2-isocyanobenzyl) indole derivative quorum sensing inhibitor and preparation method and application thereof 海南大学 2023-06-23 CN disclosed
WO-2023114472-A1 HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-06-22 WO disclosed
WO-2023059582-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 WO disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197376-A1 PYRAZINE AMIDE DERIVATIVES SIRT5, GLS2, ARG2 MEN1 3257/4885KMT2A 690/4885POLB 2259/4885
US-20250108123-A1 COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF STING1, IRF3, CGAS MEN1 1674/4885KMT2A 3683/4885POLB 1070/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 MEN1 4354/4885KMT2A 3415/4885POLB 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.